STTK
STTK
Shattuck Labs, Inc.Company Information
Recommendation Details
Healthcare holds up to 5 names drawn from Healthcare above $200M. Healthcare ranked on the positive head, composite factor and analyst rating. Positions are held for 6-21 days, each position carries a 20% stop-loss. Benchmark: S&P 500 Health Care (S5HLTH).
Company Description
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.